Composition including rilpivirine and method for treating tumors or cancer
The present invention provides a composition and method for preventing the growth of and/or treating cancerous tumors and/or delaying onset of cancer from tumor-initiating cells. The composition includes an effective amount of a compound of Formula (I) or Formula (II): or any pharmaceutically acceptable salt thereof. The composition is administered alone or in combination with one or more chemotherapeutic agents, biological agents and/or anticancer agents. The method may include administering the composition of the present invention with or without the chemotherapeutic, biological, or other cancer treatment agent to a subject in need thereof intravenously, parenterally, nasally, topically or locally, orally, or by liposome, implant or via vessel-targeted nanosuspension delivery.
1. A method for preventing growth of and/or treating a cancerous tumor and/or delaying onset of cancer from tumor-initiating cells, the method comprising: administering a composition comprising an effective amount of a compound of Formula (I) or Formula (II):
or any pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the cancerous tumor and/or cancer comprises acute lymphoblastic leukemia, chronic myelogenous leukemia, or non-Hodgkin's lymphoma.
2. The method of claim 1 , wherein said subject is a human comprising adult, juvenile, children or infants.
3. The method of claim 1 , wherein the composition is administered at least once daily.
4. The method of claim 1 , wherein the administering the composition of Formula (I) or Formula (II) is in combination with one or more chemotherapeutic agents, biological agents and/or anticancer agents, to a subject in need thereof.
5. The method of claim 4 wherein the one or more chemotherapeutic agents comprises one or more alkylating agents, anti-metabolites, antitumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, steroids, and/or any mixtures thereof; and the one or more biological agents comprises one or more vaccines, cytokines, antibodies, protein and peptide drugs and/or any mixtures thereof.
6. The method of claim 5 , wherein said alkylating agents are one or more selected from cyclophosphamide, melphalan, temozolomide, carboplatin, cisplatin, and/or oxaliplatin.
7. The method of claim 5 , wherein said anti-metabolites are one or more selected from 5-fluorouracil, 6-mercaptopurine, cytarabine, gemcitabine, and/or methotrexate.
8. The method of claim 5 , wherein said antitumor antibiotics are one or more selected from actinomycin-D, bleomycin, daunorubicin, and/or doxorubicin.
9. The method of claim 5 , wherein said topoisomerase inhibitors are one or more selected from etoposide, irinotecan, teniposide, and/or topotecan.
10. The method of claim 5 , wherein said mitotic inhibitors are one or more selected from docetaxel, estramustine, paclitaxel, vincristine, and/or vinblastine.
11. The method of claim 5 , wherein said steroids are one or more selected from prednisone, methylprednisolone, and/or dexamethasone.
12. The method of claim 5 , wherein said antibodies are one or more selected from Hu3F8, hu14.18K322A, Hu14.18-IL-2, and/or dinutuximab.
13. A composition for preventing growth of and/or treating a cancerous tumor and/or delaying onset of cancer from tumor-initiating cells, the composition comprising: an effective amount of a compound of Formula (I) or Formula (II):
or any pharmaceutically acceptable salt thereof, the composition further including one or more
chemotherapeutic agents selected from alkylating agents, anti-metabolites, antitumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, and/or steroids; or
biological agents selected from vaccines, cytokines, protein and peptide drugs, and/or antibodies; or a combination thereof; and
wherein the cancerous tumour and/or cancer comprises acute lymphoblastic leukemia, chronic myelogenous leukemia, or non-Hodgkin's lymphoma.
14. The composition of claim 13 , wherein said alkylating agents are one or more selected from cyclophosphamide, melphalan, temozolomide, carboplatin, cisplatin, and/or oxaliplatin.
15. The composition of claim 13 , wherein said anti-metabolites are one or more selected from 5-fluorouracil, 6-mercaptopurine, cytarabine, gemcitabine, and/or methotrexate.
16. The composition of claim 13 , wherein said antitumor antibiotics are one or more selected from actinomycin-D, bleomycin, daunorubicin, and/or doxorubicin.
17. The composition of claim 13 , wherein said topoisomerase inhibitors are one or more selected from etoposide, irinotecan, teniposide, and/or topotecan.
18. The composition of claim 13 , wherein said mitotic inhibitors are one or more selected from docetaxel, estramustine, paclitaxel, vincristine, and/or vinblastine.
19. The composition of claim 13 wherein said steroids are one or more selected from prednisone, methylprednisolone, and/or dexamethasone.
20. The composition of claim 13 , wherein said antibodies are one or more selected from Hu3F8, hu14.18K322A, Hu14.18-IL-2, and/or dinutuximab.
21. The composition of claim 13 , wherein said composition is formulated into one or more of the following administrative forms: a parenteral formulation, an aqueous solution, a liposome, an injectable solution, an injectable suspension, an intravenous solution, an intravenous suspension/nanosuspension, a tablet, a pill, a lozenge, a capsule, a caplet, a patch, a spray, an inhalant, a powder, a freeze-dried powder, a patch, a gel, a geltab, a suspension, a nanosuspension, a microparticle, a nanoparticle, a nanoliposome, a microgel, a pellet, a suppository, an oral suspension, an oral disintegrating tablet, an oral dispersible tablet, an oral disintegrating film, a microemulsion, a nanoemulsion and a self-emulsifying drug delivery system and/or any combination thereof.